Literature DB >> 35107690

Roles of the miR-155 in Neuroinflammation and Neurological Disorders: A Potent Biological and Therapeutic Target.

Seyed Hamidreza Rastegar-Moghaddam1,2, Alireza Ebrahimzadeh-Bideskan1,2, Sara Shahba3, Amir Mohammad Malvandi4, Abbas Mohammadipour5.   

Abstract

Neuroinflammation plays a crucial role in the development and progression of neurological disorders. MicroRNA-155 (miR-155), a miR is known to play in inflammatory responses, is associated with susceptibility to inflammatory neurological disorders and neurodegeneration, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis as well as epilepsy, stroke, and brain malignancies. MiR-155 damages the central nervous system (CNS) by enhancing the expression of pro-inflammatory cytokines, like IL-1β, IL-6, TNF-α, and IRF3. It also disturbs the blood-brain barrier by decreasing junctional complex molecules such as claudin-1, annexin-2, syntenin-1, and dedicator of cytokinesis 1 (DOCK-1), a hallmark of many neurological disorders. This review discusses the molecular pathways which involve miR-155 as a critical component in the progression of neurological disorders, representing miR-155 as a viable therapeutic target.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Brain malignancies; Epilepsy; MicroRNA-155; Neurodegenerative diseases; Stroke, RNA therapeutics

Year:  2022        PMID: 35107690     DOI: 10.1007/s10571-022-01200-z

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  84 in total

1.  Hydrogen sulfide and mesenchymal stem cells-extracted microvesicles attenuate LPS-induced Alzheimer's disease.

Authors:  Basma E Aboulhoda; Laila A Rashed; Hoda Ahmed; Eman M M Obaya; Walaa Ibrahim; Marwa A L Alkafass; Sarah A Abd El-Aal; Asmaa M ShamsEldeen
Journal:  J Cell Physiol       Date:  2021-01-22       Impact factor: 6.384

2.  In Vivo Inhibition of miR-155 Promotes Recovery after Experimental Mouse Stroke.

Authors:  Ernesto Caballero-Garrido; Juan Carlos Pena-Philippides; Tamar Lordkipanidze; Denis Bragin; Yirong Yang; Erik Barry Erhardt; Tamara Roitbak
Journal:  J Neurosci       Date:  2015-09-09       Impact factor: 6.167

3.  Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice.

Authors:  Oleg Butovsky; Mark P Jedrychowski; Ron Cialic; Susanne Krasemann; Gopal Murugaiyan; Zain Fanek; David J Greco; Pauline M Wu; Camille E Doykan; Olga Kiner; Robert J Lawson; Matthew P Frosch; Nathalie Pochet; Rachid El Fatimy; Anna M Krichevsky; Steven P Gygi; Hans Lassmann; James Berry; Merit E Cudkowicz; Howard L Weiner
Journal:  Ann Neurol       Date:  2014-11-27       Impact factor: 10.422

4.  Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease.

Authors:  A Arena; A M Iyer; I Milenkovic; G G Kovacs; I Ferrer; M Perluigi; E Aronica
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

5.  Developmental regulation and lateralisation of the α7 and α4 subunits of nicotinic acetylcholine receptors in developing rat hippocampus.

Authors:  Raheleh Baradaran; Hoda Khoshdel-Sarkarizi; Saeid Kargozar; Javad Hami; Abbas Mohammadipour; Ariane Sadr-Nabavi; Mostafa Peyvandi Karizbodagh; Hamed Kheradmand; Hossein Haghir
Journal:  Int J Dev Neurosci       Date:  2020-04-01       Impact factor: 2.457

6.  MiR-155 deletion reduces ischemia-induced paralysis in an aortic aneurysm repair mouse model: Utility of immunohistochemistry and histopathology in understanding etiology of spinal cord paralysis.

Authors:  Hamdy Awad; Anna Bratasz; Gerard Nuovo; Richard Burry; Xiaomei Meng; Hesham Kelani; Melissa Brown; Mohamed E Ramadan; Jim Williams; Lamia Bouhliqah; Phillip G Popovich; Zhen Guan; Cynthia Mcallister; Sarah E Corcoran; Brian Kaspar; D Michele Basso; José J Otero; Claudia Kirsch; Ian C Davis; Carlo Maria Croce; Jean-Jacques Michaille; Esmerina Tili
Journal:  Ann Diagn Pathol       Date:  2018-06-18       Impact factor: 2.090

7.  Neuroprotective effects of garlic extract on dopaminergic neurons of substantia nigra in a rat model of Parkinson's disease: motor and non-motor outcomes.

Authors:  Maryam Bigham; Abbas Mohammadipour; Mahmoud Hosseini; Amir Mohammad Malvandi; Alireza Ebrahimzadeh-Bideskan
Journal:  Metab Brain Dis       Date:  2021-03-03       Impact factor: 3.584

8.  Antagonist Targeting microRNA-155 Protects against Lithium-Pilocarpine-Induced Status Epilepticus in C57BL/6 Mice by Activating Brain-Derived Neurotrophic Factor.

Authors:  Zhengxu Cai; Song Li; Sheng Li; Fan Song; Zhen Zhang; Guanhua Qi; Tianbai Li; Juanjuan Qiu; Jiajia Wan; Hua Sui; Huishu Guo
Journal:  Front Pharmacol       Date:  2016-05-31       Impact factor: 5.810

Review 9.  miR-155 in the Resolution of Atherosclerosis.

Authors:  Robyn Bruen; Stephen Fitzsimons; Orina Belton
Journal:  Front Pharmacol       Date:  2019-05-14       Impact factor: 5.810

10.  Circulating miR-155 and JAK2/STAT3 Axis in Acute Ischemic Stroke Patients and Its Relation to Post-Ischemic Inflammation and Associated Ischemic Stroke Risk Factors.

Authors:  Noha Adly Sadik; Laila Ahmed Rashed; Mai Ahmed Abd-El Mawla
Journal:  Int J Gen Med       Date:  2021-04-21
View more
  3 in total

Review 1.  The Role of Human Herpesvirus 6 Infection in Alzheimer's Disease Pathogenicity-A Theoretical Mosaic.

Authors:  Constantin Romanescu; Thomas Gabriel Schreiner; Ilya Mukovozov
Journal:  J Clin Med       Date:  2022-05-29       Impact factor: 4.964

2.  NF-kB (p50/p65)-Mediated Pro-Inflammatory microRNA (miRNA) Signaling in Alzheimer's Disease (AD).

Authors:  Walter J Lukiw
Journal:  Front Mol Neurosci       Date:  2022-06-28       Impact factor: 6.261

Review 3.  Targeting miR-21 in spinal cord injuries: a game-changer?

Authors:  Amir Mohammad Malvandi; Seyed Hamidreza Rastegar-Moghaddam; Saeede Ebrahimzadeh-Bideskan; Giovanni Lombardi; Alireza Ebrahimzadeh-Bideskan; Abbas Mohammadipour
Journal:  Mol Med       Date:  2022-09-23       Impact factor: 6.376

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.